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Abstract
Background: Sulfotransferase (SULT) plays an important role in the formation of estrogen which is usually conferred as 
a risk factor for breast cancer. Polymorphism of the SULT1A1 may be closely associated with breast cancer. However, 
studies on the association between polymorphism and breast cancer have yielded inconsistent results. We performed 
a meta-analysis including ethnic subgroup and menopausal statue subgroup to investigate the association of SULT1A1 
Arg213His polymorphism with breast cancer.
Methods: PubMed, EBSCO and Web of Science databases were searched for the correlative articles up to January 2010 
(10362 breast cancer patients and 14250 controls). The risk (odds ratio, OR) was used to estimate the association 
between SULT1A1 polymorphism and breast cancer risk. All of the data from each study use either fixed-effects or 
random-effects.
Results: We found that SULT1A1 Arg213His had no exact effect to increase the risk of breast cancer (OR = 1.07, 95% CI: 
0.97-1.17, P = 0.164), but it did increase the risk of breast cancer among postmenopausal women in the dominant 
model (OR = 1.28, 95%CI: 1.04-1.58, P = 0.019). No similar effect was found among premenopausal breast cancer 
women (OR = 1.06, 95%CI: 0.88-1.27, P = 0.537). There was a significant increase in breast cancer risk among Asian 
women (OR = 2.03, 95% CI: 1.00-4.14, P = 0.051) but not Caucasian women in recessive model. There was publication 
bias among postmenopausal women subgroup (P = 0.002), however by using the trim and fill method, if the 
publication bias was the only source of the funnel plot asymmetry, it needed two more studies to be symmetrical. The 
value of Log OR did not change too much after the adjustment and the fail-safe number of missing studies that would 
bring the P-value changed was 17.
Conclusions: We concluded that the polymorphism of SULT1A1 Arg213His might be one of the high risk factors for 
breast cancer in Asian women and in postmenopausal women for all races. We should point out that the publication 
bias among postmenopausal women may partly account for the result, but the conclusion might not affected deeply 
by the publication bias.
Background
Estrogen stimulation plays an important role in human
b r e a s t  c a n c e r  c e l l  g r o w t h  a n d  d e v e l o p m e n t .  I t  w a s
reported that estrogen could affect breast cancer risk
through stimulating cellular proliferation and promoting
tumor progression[1]. It might be important to obtain a
better understanding of enzymatic mechanism in breast
cancer tissues.
Enzymatic mechanism involves in the formation of
estrogen including two main pathways. One is the sul-
fatase pathway which involves conversion of inactive
estrone sulfate into active estrone[2]. Sulfotransferase
(SULT) sulfonates estrone to inactive estrone sulfate (E1-
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S), whereas steroid sulfatase (STS) hydrolyzes estrone
sulfate to estrone. Another is the aromatase pathway
which converts androstenedione into estrone and aro-
matase inhibitor has been successfully used in breast can-
cer standard treatment[3]. However, it was reported that
aromatase manner was five hundred times lower than
sulfatase one pointed by quantitative enzymatic evalua-
tion [4]. Besides, early study showed that the conversion
of estrogen to the inactive estrogen sulfate was very
essential, as serum level of unconjugated estrone (E1) or
estradiol (E2) had 10-fold lower than the level of E1-S. In
addition, tissue concentration of E2 in breast cancer was
10 times higher than the level in plasma. The accumula-
tion of E2 in breast cancer was mainly caused by the over
expressed STS and the decreasing of SULT expression [5].
There are three families of SULTs. They are SULT1
family which is the major "phenol" SULT, sulfating a wide
range of substrates including eight subfamilies, SULT2
family and SULT4 family. SULT1A1 gene locates in chro-
mosome 16p11.2 - p12.1. Previous study reported that
exon 7 of the SULT1A1 gene contained a G to A transi-
tion at codon 213 and showed that relevant polymor-
phism significantly reduced its enzymatic activity [6].
For the above reasons, genetic studies of SULT poly-
morphisms may improve our understanding of the mech-
anism of SULT and enable us to screen for individuals at
high risk for different cancers. However a number of
studies with conflicting outcomes have been conducted
on SULT polymorphism among different cancers such as
lung, ovarian, prostate and bladder [7-10]. Besides that,
some authors had explored the potential association
between the SULT1A1 polymorphism and breast cancer
risk and it had also shown inconsistent results. Kotnis'
study showed that the polymorphism of SULT1A1
Arg213His might predispose carriers to lung cancers,
protect against colorectal cancers and increase the risk of
breast cancer to Asian women but not the Caucasian
women [11]. Recently Wang et al. meta-analyzed the rela-
tionships between SULT1A1 and breast cancer risk [12]
and concluded that there was no significant relationship
between SULT1A1 R213 H polymorphism and the risk of
breast cancer. However both meta-analysis were not per-
fect and may lead to underestimate the role of SULT1A1
polymorphism in breast carcinogenesis, because they did
not include some eligible studies and neglected the valu-
able subgroup analysis such as menopausal status. It
should be pointed out that there was new finding in
results of the present study which was never founded in
the previous. The current meta-analysis approved to be a
more precise estimation which included two more stud-
ies and a subgroup analysis according to menses status
which came out statistical significance.
Here we performed an updated meta-analysis which
was specialized in breast cancer, including 16 studies with
a subgroup analysis based on ethnicity and menopausal
status, using Arg/Arg vs His/His, Arg/Arg vs Arg/His,
dominant model (Arg/His+His/His vs Arg/Arg) and
recessive model (His/His vs Arg/Arg+Arg/His).
Methods
Identification and analysis of relevant studies
Two investigators (Yiwei Jang and Liheng Zhou) indepen-
dently obtained relevant articles through searches of
PubMed, EBSCO and Web of Science databases using the
following words: 'sulfotransferase or SULT', 'polymor-
phism' and 'breast cancer'. Studies had been case-control
design and based on SULT1A1 Arg213His polymorphism
either alone or in combination with other genes and the
language of publication was restricted to English. All of
the studies required study design, publication, breast can-
cer cases, controls selection and genotyping methods. We
excluded articles on only breast cancer patients or on
healthy persons and one case-series study. In the end,
10362 breast cancer patients and 14250 controls from 16
case-control studies were selected for this meta-analysis.
Data extraction
The following data were collected from each included
studies: first authors, year of publications, study popula-
tion (categorized as Asian, Caucasian, African and oth-
ers), sources of controls, menopausal status and the
number of different genotype in all subjects.
Statistical analysis
The risk (odds ratio, OR) was used to estimate the associ-
ation between SULT1A1 polymorphism and breast can-
cer risk, using Arg/Arg vs His/Arg, Arg/Arg vs His/His,
dominant model (Arg/His+His/His vs Arg/Arg) and
recessive model (His/His vs Arg/Arg+Arg/His). For each
study, the between-study heterogeneity was assessed
across by the chi-square based Q statistics and I-square
test. Heterogeneity was considered at either a P-value of
< 0.50 or I-square > 50% [13]. All of the data from each
study use either fixed-effects (Mantel-Haenszel's method)
or random-effects (DerSimonian and Laird's method)
model according to the heterogeneity result. If there is no
between-study heterogeneity, the two methods provide
similar results. Funnel plots and Egger's test were used to
test the possible publication bias. Sensitivity analyses
were performed to estimate the influence of individual
studies on the summary effect. For the possible publica-
tion bias, we used trim and fill method and fail-safe num-
ber to evaluate the influence to the result. In the ethnic
population analysis, statistical analysis was performed in
Asian, Caucasian, African and other populations. For
menopausal status, studies were divided into postmeno-
pausal and premenopausal status. All of the analyses were
performed by Stata 10.0 software (Stata Corporation,Jiang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:101
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College Station, TX, USA) and Comprehensive Meta-
Analysis software program (version 2.2.034, USA, 2006),
using two-sided P values.
Result
Eligible studies
Based on the search strategy, 16 studies were selected.
There are 8 studies focused on the menopausal status. All
of the studies were divided into four ethnic categories:
Asian, Caucasian, African and others. The study details
are shown in the table 1. The genotype distribution is
consistent with Hardy-Weinberg equilibrium but four
studies [14-30]. All of the studies were published from
January 2000 to January 2010.
Meta-analysis database
The details of the study characteristics and the ORs we
calculated were listed in Table 2. In the dominant model
(Arg/His+His/His vs Arg/Arg), there was between-study
heterogeneity in the odds ratios (ORs) of the studies
(Heterogeneity chi-squared = 30.09 (d.f. = 15), I-squared
= 50.2%, P = 0.012), so we used the random-effect model
to analyze the data and found that there was no relation-
ship between Arg/His+His/His genotype and the risk of
breast cancer (OR = 1.07, 95% CI: 0.97-1.17, P = 0.164). In
the recessive model (His/His vs Arg/Arg+ Arg/His), there
was no between-study heterogeneity in the odds ratios
(ORs) of the studies (Heterogeneity chi-squared = 18.25
(d.f. = 12) I-squared = 34.3%, P = 0.108). Through the
fixed-effect model we found that it was no relationship
with breast cancer risk (OR = 1.07, 95% CI: 0.97-1.17, P =
0.169). We used random-effect model (Heterogeneity
chi-squared = 31.11 (d.f. = 14) I-squared = 55.0%, P =
0.005) to analyze Arg/Arg vs Arg/His (OR = 1.06, 95%CI:
0.95-1.18, P = 0.291) (Fig. 1) and fixed-effect model (Het-
erogeneity chi-squared = 15.21 (d.f. = 12) I-squared =
21.1%, P = 0.230) to analyze Arg/Arg vs His/His (OR =
1.07, 95%CI: 0.97-1.18, P = 0.197) (Fig. 2), there was no
relationship between SULT1A1 and breast cancer risk
either. Meanwhile, we analyzed the subgroups of the
studies and found that genotype Arg213His increased the
risk of breast cancer among postmenopausal women (OR
= 1.28, 95% CI: 1.04-1.58, P = 0.019) but not in the pre-
Table 1: Characteristics of studies included in the meta-analysis
Case Control
Author Population Menses Arg/Arg Arg/His His/His Arg/Arg Arg/His His/His
MARIE-GENICA Caucasian postmenopausal 1381 1332 426 2338 2430 658
Gulyaeva Caucasian NM 23 40 19 63 61 56
Rebbeck Caucasian postmenopausal 199 226 297 259
Rebbeck African postmenopausal 85 59 193 153
Yang Asian premenopausal 622 116 0 614 112 0
Yang Asian postmenopausal 299 65 0 363 58 0
Lilla Caucasian NM 198 169 52 374 403 107
Le Marchand Others NM 801 424 114 782 484 104
Jerevall Caucasian postmenopausal 80 121 28 84 106 38
Han Asian premenopausal 92 21 3 136 23 4
Han Asian postmenopausal 68 20 5 219 38 6
Choi Asian NM 796 190 0 830 215 0
Cheng Asian NM 439 27 2 693 47 0
Sillanpaa Caucasian premenopausal 145 229 106 147 221 110
Langsenlehner Caucasian NM 201 250 47 224 212 63
Chacko Asian 76 56 8 95 41 4
Chacko Asian premenopausa 39 27 42 24
Chacko Asian postmenopausa 37 37 53 21
Tang Others NM 50 42 11 134 83 13
Zheng Others postmenopausal 55 71 29 148 136 44
Seth Caucasian NM 229 176 39 110 94 23
aNM: not mentionJ
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Table 2: ORs of studies included in the meta-analysis
OR(95%CI) OR(95%CI OR(95%CI) OR(95%CI)
Author Population Menses Year Arg/His+His/His vs 
Arg/Arg
His/His vs Arg/Arg+ 
Arg/His
Arg/Arg vs Arg/His Arg/Arg vs His/His
MARIE-GENICA Caucasian postmenopausal 2009 0.96(0.88-1.05) 1.14 (1.00-1.30) 0.93 (0.84-1.02) 1.10 (0.95-1.26)
Gulyaeva Caucasian NM 2008 1.38(0.78-2.44) 0.67 (0.37-1.22) 1.80 (0.96-3.35) 0.93 (0.46-1.88)
Rebbeck Caucasian postmenopausal 2007 1.19(0.97-1.47) Excluded Excluded Excluded
Rebbeck African postmenopausal 2007
Yang Asian premenopausal 2005 1.13(0.90-1.42) Excluded 1.13 (0.90-1.42) Excluded
Yang Asian postmenopausal 2005
Lilla Caucasian NM 2005 0.82(0.65-1.03) 1.03 (0.72-1.47) 0.79 (0.62-1.02) 0.92 (0.63-1.33)
Le Marchand Others NM 2005 0.89(0.77-1.04) 1.13 (0.86-1.49) 0.86 (0.73-1.01) 1.07 (0.81-1.42)
Jerevall Caucasian postmenopausal 2005 1.09(0.74-1.59) 0.70 (0.41-1.18) 1.20 (0.80-1.79) 0.77 (0.44-1.38)
Han Asian premenopausal 2005 1.53(1.02-2.31) 1.66 (0.64-4.26) 1.49 (0.96-2.31) 1.76 (0.69-4.58)
Han Asian postmenopausal 2005
Choi Asian NM 2005 0.92(0.74-1.15) Excluded 0.92 (0.74-1.15) Excluded
Cheng Asian NM 2005 0.97(0.60-1.57) 7.93(0.38-165.68) 0.91 (0.58-1.48) 7.89 (0.38-164.72)
Sillanpaa Caucasian premenopausal 2005 1.03(0.78-1.35) 0.95 (0.70-1.28) 1.05 (0.78-1.41) 0.98 (0.69-1.39)
Langsenlehner Caucasian NM 2004 1.20(0.94-1.55) 0.72 (0.48-1.08) 1.31 (1.01-1.71) 0.83 (0.55-1.27)
Chacko Asian 2004 1.78(1.09-2.89) 2.06 (0.61-7.01) 1.71 (1.03-2.82) 2.50 (0.73-8.62)
Chacko Asian premenopausal 2004
Chacko Asian postmenopausal 2004
Tang Others NM 2003 1.48(0.93-2.36) 2.00 (0.86-4.62) 1.36 (0.83-2.22) 2.27 (0.95-5.39)
Zheng Others postmenopausal 2001 1.49(1.01-2.22) 1.49 (0.89-2.48) 1.41 (0.92-2.14) 1.77 (1.01-3.11)
Seth Caucasian NM 2000 0.88(0.64-1.22) 0.85 (0.50-1.47) 0.90 (0.64-1.26) 0.82 (0.46-1.43)
aNM: not mentionJiang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:101
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menopausal women (OR = 1.06, 95% CI: 0.88-1.27, P =
0.537) by both M-H method and D-L method. Because of
the different heterogeneity results for postmenopausal
women (Heterogeneity chi-squared = 20.01 (d.f. = 6) I-
squared = 70%, P = 0.003) and premenopausal women
(Heterogeneity chi-squared = 0.73 (d.f. = 3) I-squared =
0.0%, P = 0.866), we used both M-H method and D-L
method. For all the studies included in the menses sub-
group (Heterogeneity chi-squared = 20.74 (d.f. = 10) I-
squared = 51.8%, P = 0.023), there was also statistical sig-
nificance (OR = 1.19, 95% CI: 1.03-1.36, P = 0.017) (Fig.
3). As for the ethnic subgroups, we used fixed-effects to
analyze the studies. We found that racial difference influ-
enced the relationship between the polymorphism and
the breast cancer risk, especially in Asian women (M-H
method, Heterogeneity chi-squared = 0.95 (d.f. = 2) I-
squared = 0.0%, P = 0.621, OR = 2.03, 95% CI: 1.00-4.14, P
= 0.051) but not Caucasian women (M-H method, Het-
erogeneity chi-squared = 10.12 (d.f. = 6) I-squared =
40.7%, P = 0.120, OR = 1.02, 95% CI: 0.92-1.13, P = 0.678)
(Fig. 4).
Publication bias and Sensitivity analyses
We performed the funnel plots and Egger's test to assess
the publication bias. As a result there was no publication
bias in recessive model (t = 0.16, P = 0.875), Arg/Arg vs
His/His model (t = 1.09, P = 0.299), subgroup for popula-
tion (t = 0.02, P = 0.985) (Fig. 5). But there was publica-
tion bias for all population in dominant model (t = 2.82, P
= 0.014) (Fig. 6) and Arg/Arg vs Arg/His model (t = 3.21,
P = 0.007). This might be a limitation for our analysis
because studies with null findings, especially those with
small sample size, are less likely to be published. Also
there was a publication bias (for postmenopausal women:
t = 5.96, P = 0.002) as the result suggested. By using the
trim and fill method, we showed that, if the publication
bias was the only source of the funnel plot asymmetry, it
needed two more studies to be symmetrical. The value of
Log OR did not change too much after the adjustment
Figure 1 Forest plot of meta-analysis on the association of SULT1A1 Arg213His with breast cancer risk in all population by Arg/Arg vs Arg/
His model. The size of the square box is proportional to the weight that each study contributes in the meta-analysis. The overall estimate and confi-
dence interval are marked by a diamond. Symbols on the right of the line indicate OR > 1 and symbols on the left of the line indicate OR < 1.
NOTE: Weights are from random effects analysis
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(Fig. 7). Beside that, the fail-safe number of missing stud-
ies that would bring the P-value changed was 17. The
influence of individual studies on the summary effect
estimate was performed by sensitivity analyses on the
overall OR (Fig. 8). No individual study affected the over-
all OR, since omission of any single study made no mate-
rially huge difference.
Discussion
Prolonged exposure to high level of estrogen still has
been appreciated as a risk factor for breast carcinogene-
sis. From previous study we knew that SULT1A1 was an
important enzyme in xenobiotic metabolism because it
had broad substrate specificity with a high affinity for
many compounds [31,32], furthermore SULT immunore-
activity was associated with tumor size (P = 0.0030) or
lymph node status (P = 0.0027) [4]. This meta-analysis
with 16 studies demonstrates no significant association of
SULT1A1 polymorphism with breast cancer risk in the
overall study populations which is similar with the previ-
ous result [12]. One reason may be that the effect of a sin-
gle nucleotide polymorphism might have a limited
impact on breast cancer risk. The result indicated that
multiple SNP-based approaches rather than a single
nucleotide polymorphism-based strategy may provide
more exact information on relationship between
SULT1A1 and breast cancer. Future research should be
directed to evaluate the effect of other polymorphisms.
Another reason may be that SULT1A1 polymorphism has
relation to breast cancer in part of the women and the
whole population analysis may weaken this relationship.
Therefore subgroup analysis should be done to find
whether it is one of the breast cancer risk factors.
From the ethnic subgroup, we found that there was sig-
nificant result among the different race. SULT1A1 R213
H increased the risk of breast cancer among Asian
women but not Caucasian women in recessive model
(His/His vs Arg/Arg+Arg/His) which was consistent with
the previous studies. Carlsten had reported the similar
phenomenon for GSTM1 polymorphism which con-
Figure 2 Forest plot of meta-analysis on the association of SULT1A1 Arg213His with breast cancer risk in all population by Arg/Arg vs His/
His model. The size of the square box is proportional to the weight that each study contributes in the meta-analysis. The overall estimate and confi-
dence interval are marked by a diamond. Symbols on the right of the line indicate OR > 1 and symbols on the left of the line indicate OR < 1.
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ferred a significantly increased risk of lung cancer to East
Asians but not to Caucasians[33]. The frequency of
SULT1A1 allele was different among the ethnic groups.
From the previous study we knew that the maximum
value of the His allele frequency is 0.18 in the Asian,
which was much lower than the minimum value 0.23 in
the Caucasian [12]. The potential explanation is that the
allele frequencies in Asian population are very low and
are fairly different from those observed in Caucasian and
A f r i c a n s  [ 3 1 ] .  I t  a l s o  s h o u l d  b e  p o i n t e d  o u t  t h a t  o n l y
three studies included in this analysis. More studies
needed to confirm the result.
In the subgroup analysis of different menopausal statue,
we surprisingly found that SULT1A1 polymorphism
increased the risk of breast cancer among postmeno-
pausal women but not among premenopausal women. In
the Yang's research, a possible association between
SULT1A1 and breast cancer risk was also suggested for
postmenopausal women [17]. However, two thirds of
breast cancers occur during the postmenopausal period
when the ovaries have ceased to be functional [32]. It was
also reported that higher serum concentrations of estro-
gens were associated with increased breast cancer risk in
postmenopausal women [34]. Early studies indicated that
several factors could be implicated in this process, includ-
ing higher steroids which were gained from plasma and
the potent E2 which was formed by the breast cancer tis-
sue itself [5]. However, the serum hormone levels change
with the menstrual cycle and the cycle length varies indi-
vidually, so it is difficult to address the association of hor-
mone levels and breast cancer risk among premenopausal
women [35]. Multiple factors may act on the breast can-
Figure 3 Forest plot displaying a fixed-effects and random-effects meta-analysis on the association of SULT1A1 Arg213His with breast can-
cer risk by menopausal statue in the dominant model. The size of the square box is proportional to the weight that each trial contributes in the 
meta-analysis. The overall estimate and confidence interval are marked by a diamond. Symbols on the right of the line indicate OR > 1 and symbols 
on the left of the line indicate OR < 1.
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Figure 4 Forest plot displaying a random-effects meta-analysis on the association of SULT1A1 Arg213His with breast cancer risk by race in 
the recessive model. The size of the square box is proportional to the weight that each trial contributes in the meta-analysis. The overall estimate 
and confidence interval are marked by a diamond. Symbols on the right of the line indicate OR > 1 and symbols on the left of the line indicate OR < 1.
.
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Figure 5 Funnel plots for publication bias for population sub-
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cer risk among premenopausal women, but our analysis
supported that the polymorphism of SULT1A1 may have
significant effects on the relationship between breast can-
cer risk and SULT1A1 Arg213His polymorphism among
the postmenopausal women. Due to the publication bias
we found, the result may remain uncertain. By the trim
and fill method and the fail-safe number, we can find that
the publication bias may have a small effect on the result.
So the publication bias may partly account for the result.
There were some limitations of this meta-analysis.
First, the unavailable genotype data from some articles
was the main limitation. We did everything possible to
obtain the full data on the subjects, and about 75 percent
of subjects involved in various ethnic populations. Lack
of original data of each study may prevent more detailed
analyses such as joint effects of SNP-SNP which we hope
will be demonstrated by the following studies. Next, some
controls were selected from benign breast disease which
have potential risks of developing breast cancer might
lead to misclassification. These limitations may also
explain the publication bias in postmenopausal women.
Conclusion
In a conclusion, SULT1A1 Arg213His may be associated
with breast cancer risk in Asian women and postmeno-
pausal women among all races, although there are no
exact effects to increase the risk of breast cancer in pre-
menopausal women. Due to the publication bias we
found, it encourages more studies to pay attention on the
menopausal statue in further researches.
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